Ipilimumab | Drug Guide - MedSchool
Sign up to start your free trial of MedSchool Premium!Get Started
 
Drug Guide
 
 
#
A
B
C
D
E
F
G
H
I
K
L
M
N
O
P
Q
R
S
T
U
V
W
Z
 

Ipilimumab

Bookmark
  •  
    IV infusion
    Ipilimumab
    Yervoy 
    • Mechanism of Action
    • A monoclonal antibody against cytotoxic T-lymphocyte antigen 4 (CTLA-4), a T cell inhibitory molecule that binds to B7 and prevents its binding to CD28.
      The B7 : CD28 complex normally potentiates the binding of T cell receptors to MHC/antigen complexes on antigen-presenting cells, stimulating T cell proliferation and differentiation.
      CTLA-4 is expressed on the surface of T cells after activation, and provides inhibitory signalling to T cells by binding B7.
      Binding to anti-CTLA-4 antibodies to CTLA-4 leaves B7 free to continue to bind to CD28 and provide ongoing T cell costimulation.

Clinical Use

    • Indications
    • Unresectable or metastatic melanoma
    • Intermediate / poor risk advanced renal cell carcinoma
    • Adverse Effects
    • Endocrinopathies - hypopituitarism, hypothyroidism, adrenal insufficiency
    • GI toxicity - colitis
    • Hepatotoxicity - LFT derangement
    • Skin - rash / pruritis
    • Nausea / vomiting / diarrhoea
    • Fatigue
    • Headache
    • Tremor
    • Cough
 
Feedback